Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal J Meropol

Showing results (141-150 of 226) with videos related to

Pageof 23
Sort By:
Practical Radiation Oncology|March 29, 2014
Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinomaLauren M Tait, Joshua E Meyer, Erin McSpadden, et al.
Journal of the National Cancer Institute|December 24, 2019
Developing and Sustaining an Effective and Resilient Oncology Careforce: Opportunities for ActionSamuel U Takvorian, Erin Balogh, Sharyl Nass, et al.
The Oncologist|April 5, 2019
Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World PracticeRavi B Parikh, Matthew D Galsky, Bishal Gyawali, et al.
Plos One|January 23, 2019
Surgical approach and the impact of epidural analgesia on survival after esophagectomy for cancer: A population-based retrospective cohort studyKenneth C Cummings Iii, Tzuyung Doug Kou, Amitabh Chak, et al.
Urologic Oncology|September 8, 2018
Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologistsSimon P Kim, Neal J Meropol, Cary P Gross, et al.
British Journal of Cancer|November 22, 2017
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined responseAngela Lamarca, Jorge Barriuso, Matthew Kulke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661Gini F Fleming, Neal J Meropol, Gary L Rosner, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2002
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexedNancy L Lewis, Richard Scher, James M Gallo, et al.
Cancer|November 7, 2008
Cancer patient preferences for quality and length of lifeNeal J Meropol, Brian L Egleston, Joanne S Buzaglo, et al.
Gastrointestinal Cancer Research : GCR|November 2, 2011
Decreased Posttreatment SUV on PET Scan Is Associated With Improved Local Control in Medically Inoperable Esophageal CancerNavesh K Sharma, Joshua S Silverman, Tianyu Li, et al.
Pageof 23

Showing results (141-150 of 226) with videos related to

Sort By:
Pageof 23
Practical Radiation Oncology|March 29, 2014
Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinomaLauren M Tait, Joshua E Meyer, Erin McSpadden, et al.
Journal of the National Cancer Institute|December 24, 2019
Developing and Sustaining an Effective and Resilient Oncology Careforce: Opportunities for ActionSamuel U Takvorian, Erin Balogh, Sharyl Nass, et al.
The Oncologist|April 5, 2019
Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World PracticeRavi B Parikh, Matthew D Galsky, Bishal Gyawali, et al.
Plos One|January 23, 2019
Surgical approach and the impact of epidural analgesia on survival after esophagectomy for cancer: A population-based retrospective cohort studyKenneth C Cummings Iii, Tzuyung Doug Kou, Amitabh Chak, et al.
Urologic Oncology|September 8, 2018
Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologistsSimon P Kim, Neal J Meropol, Cary P Gross, et al.
British Journal of Cancer|November 22, 2017
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined responseAngela Lamarca, Jorge Barriuso, Matthew Kulke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661Gini F Fleming, Neal J Meropol, Gary L Rosner, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2002
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexedNancy L Lewis, Richard Scher, James M Gallo, et al.
Cancer|November 7, 2008
Cancer patient preferences for quality and length of lifeNeal J Meropol, Brian L Egleston, Joanne S Buzaglo, et al.
Gastrointestinal Cancer Research : GCR|November 2, 2011
Decreased Posttreatment SUV on PET Scan Is Associated With Improved Local Control in Medically Inoperable Esophageal CancerNavesh K Sharma, Joshua S Silverman, Tianyu Li, et al.
Pageof 23